FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000460882> ?p ?o ?g. }

• W2000460882 endingPage "732" @default.
• W2000460882 startingPage "725" @default.
• W2000460882 abstract "Purpose: To evaluate the prognostic significance of thymidine phosphorylase (TP) and coexpression of cyclooxygenase-2 (COX-2)/TP, and to investigate the relationship between COX-2 and TP expression in squamous cell carcinoma of the uterine cervix. Methods and Materials: Cancer specimens from 75 patients with International Federation of Gynecology and Obstetrics Stage IIB squamous cell carcinoma of the uterine cervix who had undergone radiotherapy and concurrent chemotherapy were immunohistochemically stained with COX-2 and TP antibodies and scored. The prognostic significance of their expression status, and the relationship between COX-2 and TP was investigated. Results: TP predominantly stained cytoplasm and the cell membrane of the tumor cells mainly in a diffuse and intense manner. TP was negative (<10% distribution) in 17%, 1+ (10–50%) in 25%, and 2+ (>50%) in 57% of patients. TP overexpression was related to a marginal prognostic significance of a poor 5-year overall survival (p = 0.082, log-rank test) and a high locoregional recurrence rate (p < 0.1, chi-square test). COX-2 and TP coexpression was observed in 24% of patients and was significantly related to poor 5-year disease-free and overall survival rates (p = 0.0083 and p = 0.025, respectively), a high pelvic lymph node involvement rate, a poor response to treatment, and a greater incidence of locoregional recurrence (p < 0.05). By multivariate analyses, only COX-2, TP, and coexpression of COX-2/TP were significant independent prognostic indicators of patient survival. All tumors showed 1+ or 2+ TP expression when COX-2 was positive, and no tumor expressed COX-2 when TP was negative (p = 0.03). In contrast, 77% of tumors expressed 1+ or 2+ TP without the synchronous expression of COX-2. Conclusions: Thymidine phosphorylase expression or COX-2/TP coexpression may be used as a molecular prognostic marker for squamous cell carcinoma of the uterine cervix. TP appears to be an important downstream molecule of COX-2 during angiogenesis and may be a new target for the treatment of uterine cervical cancer. Purpose: To evaluate the prognostic significance of thymidine phosphorylase (TP) and coexpression of cyclooxygenase-2 (COX-2)/TP, and to investigate the relationship between COX-2 and TP expression in squamous cell carcinoma of the uterine cervix. Methods and Materials: Cancer specimens from 75 patients with International Federation of Gynecology and Obstetrics Stage IIB squamous cell carcinoma of the uterine cervix who had undergone radiotherapy and concurrent chemotherapy were immunohistochemically stained with COX-2 and TP antibodies and scored. The prognostic significance of their expression status, and the relationship between COX-2 and TP was investigated. Results: TP predominantly stained cytoplasm and the cell membrane of the tumor cells mainly in a diffuse and intense manner. TP was negative (<10% distribution) in 17%, 1+ (10–50%) in 25%, and 2+ (>50%) in 57% of patients. TP overexpression was related to a marginal prognostic significance of a poor 5-year overall survival (p = 0.082, log-rank test) and a high locoregional recurrence rate (p < 0.1, chi-square test). COX-2 and TP coexpression was observed in 24% of patients and was significantly related to poor 5-year disease-free and overall survival rates (p = 0.0083 and p = 0.025, respectively), a high pelvic lymph node involvement rate, a poor response to treatment, and a greater incidence of locoregional recurrence (p < 0.05). By multivariate analyses, only COX-2, TP, and coexpression of COX-2/TP were significant independent prognostic indicators of patient survival. All tumors showed 1+ or 2+ TP expression when COX-2 was positive, and no tumor expressed COX-2 when TP was negative (p = 0.03). In contrast, 77% of tumors expressed 1+ or 2+ TP without the synchronous expression of COX-2. Conclusions: Thymidine phosphorylase expression or COX-2/TP coexpression may be used as a molecular prognostic marker for squamous cell carcinoma of the uterine cervix. TP appears to be an important downstream molecule of COX-2 during angiogenesis and may be a new target for the treatment of uterine cervical cancer." @default.
• W2000460882 created "2016-06-24" @default.
• W2000460882 creator A5001896186 @default.
• W2000460882 creator A5002350066 @default.
• W2000460882 creator A5016101715 @default.
• W2000460882 creator A5030066675 @default.
• W2000460882 creator A5064985612 @default.
• W2000460882 creator A5073263176 @default.
• W2000460882 creator A5075677192 @default.
• W2000460882 date "2005-07-01" @default.
• W2000460882 modified "2023-10-17" @default.
• W2000460882 title "Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy" @default.
• W2000460882 cites W178977003 @default.
• W2000460882 cites W1876325581 @default.
• W2000460882 cites W1963652627 @default.
• W2000460882 cites W1971334952 @default.
• W2000460882 cites W1987207125 @default.
• W2000460882 cites W1988548909 @default.
• W2000460882 cites W1989762558 @default.
• W2000460882 cites W2008220254 @default.
• W2000460882 cites W2015530132 @default.
• W2000460882 cites W2017929299 @default.
• W2000460882 cites W2038962258 @default.
• W2000460882 cites W2042033090 @default.
• W2000460882 cites W2043066164 @default.
• W2000460882 cites W2044761146 @default.
• W2000460882 cites W2050623189 @default.
• W2000460882 cites W2058118671 @default.
• W2000460882 cites W2058777317 @default.
• W2000460882 cites W2069517601 @default.
• W2000460882 cites W2078827556 @default.
• W2000460882 cites W2094242183 @default.
• W2000460882 cites W2094810573 @default.
• W2000460882 cites W2107359522 @default.
• W2000460882 cites W2117497670 @default.
• W2000460882 cites W2133304803 @default.
• W2000460882 cites W2139409858 @default.
• W2000460882 cites W2150253014 @default.
• W2000460882 cites W2153226970 @default.
• W2000460882 cites W2154526832 @default.
• W2000460882 cites W2165494849 @default.
• W2000460882 cites W2167602806 @default.
• W2000460882 cites W2202296124 @default.
• W2000460882 cites W2612574275 @default.
• W2000460882 cites W3159026205 @default.
• W2000460882 cites W60298408 @default.
• W2000460882 cites W649451551 @default.
• W2000460882 doi "https://doi.org/10.1016/j.ijrobp.2004.10.044" @default.
• W2000460882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15936552" @default.
• W2000460882 hasPublicationYear "2005" @default.
• W2000460882 type Work @default.
• W2000460882 sameAs 2000460882 @default.
• W2000460882 citedByCount "13" @default.
• W2000460882 countsByYear W20004608822012 @default.
• W2000460882 countsByYear W20004608822013 @default.
• W2000460882 countsByYear W20004608822016 @default.
• W2000460882 countsByYear W20004608822020 @default.
• W2000460882 crossrefType "journal-article" @default.
• W2000460882 hasAuthorship W2000460882A5001896186 @default.
• W2000460882 hasAuthorship W2000460882A5002350066 @default.
• W2000460882 hasAuthorship W2000460882A5016101715 @default.
• W2000460882 hasAuthorship W2000460882A5030066675 @default.
• W2000460882 hasAuthorship W2000460882A5064985612 @default.
• W2000460882 hasAuthorship W2000460882A5073263176 @default.
• W2000460882 hasAuthorship W2000460882A5075677192 @default.
• W2000460882 hasConcept C121608353 @default.
• W2000460882 hasConcept C126322002 @default.
• W2000460882 hasConcept C142724271 @default.
• W2000460882 hasConcept C143998085 @default.
• W2000460882 hasConcept C146357865 @default.
• W2000460882 hasConcept C151730666 @default.
• W2000460882 hasConcept C2776694085 @default.
• W2000460882 hasConcept C2776735402 @default.
• W2000460882 hasConcept C2777546739 @default.
• W2000460882 hasConcept C2777740455 @default.
• W2000460882 hasConcept C2780849966 @default.
• W2000460882 hasConcept C50382708 @default.
• W2000460882 hasConcept C509974204 @default.
• W2000460882 hasConcept C71924100 @default.
• W2000460882 hasConcept C86803240 @default.
• W2000460882 hasConcept C90924648 @default.
• W2000460882 hasConceptScore W2000460882C121608353 @default.
• W2000460882 hasConceptScore W2000460882C126322002 @default.
• W2000460882 hasConceptScore W2000460882C142724271 @default.
• W2000460882 hasConceptScore W2000460882C143998085 @default.
• W2000460882 hasConceptScore W2000460882C146357865 @default.
• W2000460882 hasConceptScore W2000460882C151730666 @default.
• W2000460882 hasConceptScore W2000460882C2776694085 @default.
• W2000460882 hasConceptScore W2000460882C2776735402 @default.
• W2000460882 hasConceptScore W2000460882C2777546739 @default.
• W2000460882 hasConceptScore W2000460882C2777740455 @default.
• W2000460882 hasConceptScore W2000460882C2780849966 @default.
• W2000460882 hasConceptScore W2000460882C50382708 @default.
• W2000460882 hasConceptScore W2000460882C509974204 @default.
• W2000460882 hasConceptScore W2000460882C71924100 @default.
• W2000460882 hasConceptScore W2000460882C86803240 @default.
• W2000460882 hasConceptScore W2000460882C90924648 @default.
• W2000460882 hasIssue "3" @default.

• next